ST. LOUIS, May 12, 2015 /PRNewswire/ -- Sigma-Aldrich® Corporation (NASDAQ: SIAL)
today announced that SAFC® Commercial
(www.sigma-aldrich.com/safc), its custom manufacturing services
business unit, has completed the expansion of its St. Louis facility to support commercial-scale
antibody drug conjugate (ADC) manufacturing. The facility is in
final validation and expected to go online as planned in the third
quarter of 2015. Once validated, customers will benefit from
working with a single supplier from discovery to
commercialization.
Designed to meet SafeBridge® category 4 compound
handling to safely accommodate usage of highly-active compounds,
the St. Louis expansion creates
commercial-scale manufacturing capacity for ADCs and other targeted
therapies. The expanded capabilities in St. Louis are further enhanced by expanded
commercial capacity for highly-active manufacturing and storage at
the Company's Madison, Wis.
facility.
SAFC's offers include cell-line engineering and media, linkers
and payloads, along with significant conjugation expertise using
both highly-active and non-potent compounds. The St. Louis expansion complements other recent
additions in ADC capabilities, including the announcement of SAFC's
ADC ExpressSM service for preclinical ADC and
bioconjugation services, and a collaboration with industry leader
Baxter BioPharma Solutions for formulation and fill/finish
services.
"The ADC market is a growing market, and is expected to expand
over the next few years. This strategic expansion is the latest in
a series of enhancements in our ADC offering designed to support
this important therapeutic area and to help our customers to
seamlessly scale ADC production from preclinical to commercial
phases," said Gilles Cottier,
President of SAFC. "Our offer can bring customers' molecules to the
clinic faster, with the ease of working with one supplier from
start to finish. With the added support of our recently launched
ADC Express service, we believe SAFC presents the most
comprehensive offer in the contract manufacturing market."
To learn more about SAFC's ADC capabilities, visit:
http://www.sigmaaldrich.com/safc-adc.
The foregoing release contains forward-looking statements
that can be identified by terminology such as "is expected," "will
benefit," "can bring," or similar expressions, or by expressed or
implied discussions regarding potential future revenues from
products derived therefrom. You should not place undue reliance on
these statements. Such forward-looking statements reflect the
current views of management regarding future events, and involve
known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future
results, performance or achievements expressed or implied by such
statements. There can be no guarantee that expansion of any
facility or additions in capacity will enable the Company to
achieve any particular levels of revenue in the future. In
particular, management's expectations regarding the facility and
added capacity could be affected by, among other things, the
Company's ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general;
government, industry and general public pricing pressures; the
impact that the foregoing factors could have on the values
attributed to the Company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About SAFC: SAFC Commercial,
the custom manufacturing and services business unit of
Sigma-Aldrich Corporation, is recognized as a top 10 global
specialty chemicals and biologics supplier. As a trusted
manufacturer for the life science and high-technology industries,
SAFC works closely with customers to resolve development challenges
and accelerate the product pipeline using its global "Centers of
Excellence" and dedicated manufacturing facilities. Its rich
portfolio includes high-purity inorganic materials for
high-technology applications, critical raw materials and extensive
biologics safety testing services for biopharmaceutical
manufacturing, and complex, highly-active APIs and key
intermediates for pharmaceutical manufacturing. For more
information, visit
www.sigma-aldrich.com/safc.
About Sigma-Aldrich: Sigma-Aldrich, a
leading Life Science and Technology company focused on enhancing
human health and safety, manufactures and distributes 250,000
chemicals, biochemicals and other essential products to more than
1.4 million customers globally in research and applied labs as well
as in industrial and commercial markets. With three distinct
business units - Research, Applied and SAFC Commercial
- Sigma-Aldrich is committed to enabling science to
improve the quality of life. The Company operates in 37 countries,
has approximately 9,300 employees worldwide and had sales
of $2.79 billion in 2014. For more information about
Sigma-Aldrich, please visit its website
at www.sigma-aldrich.com.
©2015 Sigma-Aldrich Co. LLC. All rights reserved.
Sigma-Aldrich and SAFC are
trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered
in the U.S. and other countries.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/safc-completes-adc-commercial-manufacturing-capacity-expansion-in-st-louis-300081190.html
SOURCE Sigma-Aldrich Corporation